PDCD1 and colorectal carcinoma: The first-in-human study of budigalimab demonstrated that it was well tolerated and safe and exhibited an efficacy comparable to that of other PD-1 inhibitors approved for clinical use (180, 181), suggesting that it could be a promising new treatment option for patients with CRC.